Relmada Therapeutics (NASDAQ:RLMD – Get Free Report) is scheduled to issue its quarterly earnings data after the market closes on Wednesday, August 7th. Analysts expect the company to announce earnings of ($0.83) per share for the quarter. Individual interested in participating in the company’s earnings conference call can do so using this link.
Relmada Therapeutics (NASDAQ:RLMD – Get Free Report) last announced its earnings results on Wednesday, May 8th. The company reported ($0.72) EPS for the quarter, beating the consensus estimate of ($0.90) by $0.18. On average, analysts expect Relmada Therapeutics to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.
Relmada Therapeutics Stock Down 2.4 %
Shares of RLMD traded down $0.08 during mid-day trading on Tuesday, reaching $3.31. 25,959 shares of the stock traded hands, compared to its average volume of 177,597. The stock has a fifty day simple moving average of $3.38 and a 200 day simple moving average of $4.18. Relmada Therapeutics has a 12-month low of $2.41 and a 12-month high of $7.22. The firm has a market cap of $99.86 million, a price-to-earnings ratio of -1.05 and a beta of 0.50.
Wall Street Analysts Forecast Growth
Read Our Latest Stock Report on Relmada Therapeutics
About Relmada Therapeutics
Relmada Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system diseases (CNS) and other disorders in the United States. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a N-methyl-D-aspartate receptor antagonist which is in phase 3 clinical trial for the adjunctive or monotherapy treatment of major depressive disorder.
Featured Articles
- Five stocks we like better than Relmada Therapeutics
- Are These Liquid Natural Gas Stocks Ready For An Upside Bounce?
- Uber’s Earnings Beat: Rideshare and Delivery Surge
- How to Calculate Options Profits
- Hims & Hers Reports Stellar Quarter: Stock Set for a Rally
- With Risk Tolerance, One Size Does Not Fit All
- Cloudflare Stock Flares Up on Solid EPS Beat and Raised Guidance
Receive News & Ratings for Relmada Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Relmada Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.